Hyper-Glycosylation as a Central Metabolic Driver of Alzheimer’s Disease

Tara R. Hawkinson, Zizhen Liu, Roberto A. Ribas, Terrymar Medina, Rikke S. Nielsen, Harrison A. Clarke, Xin Ma, Ariel Mueller, Antonio Plasencia, Alexander L. Shear, Suzanne Simpson, Charles M. Soto, Jessica Sudderth, Feng Cai, Alex R. Cantrell, Matthieu G. Colpert, Cameron J. Shedlock, Lei Wu, Lyndsay E.a. Young, Damon D. Kooser, Li Chen, A Ryan, Parastoo Azadi, Ralph J. DeBerardinis, Stefan Prokop, Derek B. Allison, Yu Huang, Xing He, Jiang Bian, Craig W. Vander Kooi, Matthew S. Gentry, Ramon C. SunbioRxiv 2025 · DOI

TL;DR

This study reveals that "hyper-glycosylation" – an overproduction of complex sugar molecules attached to proteins – is a key metabolic hallmark of Alzheimer's Disease (AD). By using advanced imaging and tracing techniques, the researchers demonstrate that this overproduction is driven by increased glycan biosynthesis and actively contributes to cognitive decline, suggesting glycan metabolism as a novel therapeutic target.

What Problem Does This Paper Address?

Alzheimer's Disease (AD) is a devastating neurodegenerative disorder, and while metabolic disruptions are known to play a role, their precise involvement in AD's molecular etiology remains unclear. Specifically, the complex world of glycans (sugar chains attached to proteins and lipids) and their role in AD pathology has been largely underexplored. This paper aims to fill this gap by investigating whether altered glycan metabolism, particularly hyper-glycosylation, is a central driver of AD progression, rather than just a consequence of the disease.

Methods

The researchers employed a multi-pronged approach:

  • Spatial Multiomics (MALDI-MSI): They used multiplexed matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to simultaneously map metabolites, lipids, and glycans within specific regions of brain tissue from both human post-mortem samples and AD mouse models. This allows for a high-resolution understanding of molecular distributions.
  • Stable Isotope Tracing (Pulse-Chase): To understand the dynamics of glycan synthesis and turnover, they used a 13C-enriched liquid diet. This "pulse-chase" method allows researchers to track newly synthesized glycans (pulse) and then observe how they are degraded or recycled over time (chase).
  • Genetic and Dietary Interventions: To test the functional impact of hyper-glycosylation, they used genetic knockdown of a key enzyme in glycan biosynthesis (PGM3) and dietary supplementation with glucosamine (a precursor for glycan synthesis) in AD mouse models.
  • Human EHR Analysis: They conducted a retrospective analysis of electronic health records to correlate glucosamine supplementation with clinical outcomes (mortality, progression from MCI to AD) in human patients.
  • Glycoproteomics: To identify which specific proteins are affected by hyper-glycosylation, they performed glycoproteomic analysis on brain samples.

Datasets

  • Human Post-Mortem Brain Samples: Samples from cognitively normal individuals and individuals with Alzheimer's Disease, stratified by Braak staging.
  • 5xFAD Mouse Model: A well-established mouse model of AD.
  • Wild-Type (WT) Mouse Model: Control mice.
  • Human Electronic Health Records (EHR): Data from over 50,000 patients from the University of Florida Health system, including those diagnosed with MCI, AD, and ADRD.

Key Insights and Ideas

  • Hyper-glycosylation is a conserved hallmark of AD: This phenotype was observed in both human AD brains and the 5xFAD mouse model, suggesting it's a fundamental aspect of the disease.
  • Increased glycan biosynthesis, not reduced degradation, drives hyper-glycosylation: The isotope tracing experiments clearly showed that the AD brain is actively making more glycans, rather than failing to break them down. This points to an overactive metabolic pathway.
  • Glucosamine supplementation exacerbates AD pathology: This was a crucial finding. Giving AD mice glucosamine (a precursor) worsened their cognitive deficits and increased glycan levels, directly linking increased glycan synthesis to disease progression.
  • Targeting glycan biosynthesis can be protective: Genetically reducing glycan biosynthesis in AD mice improved their cognitive function, demonstrating that modulating this pathway can have therapeutic benefits.
  • Glucosamine supplementation is linked to worse outcomes in human AD patients: The EHR analysis revealed a concerning association between glucosamine use and increased mortality and faster progression to AD in human patients, reinforcing the animal model findings.
  • Neurons are likely the primary site of aberrant glycosylation: Glycoproteomic analysis suggested that the affected glycoproteins are largely neuronal membrane proteins, implicating neuronal function directly.

Key Results

  • Spatial glycomics revealed significantly elevated glycan abundance in both grey and white matter of AD brains compared to controls, with a progressive increase across Braak stages.
  • In 5xFAD mice, hyper-glycosylation was most pronounced in the cortex, hippocampus, and thalamus.
  • Stable isotope tracing showed a significant increase in 13C enrichment of glycans in 5xFAD mice during the pulse phase, indicating increased biosynthesis.
  • Genetic knockdown of PGM3 in 5xFAD mice improved social memory performance, while glucosamine supplementation worsened it.
  • Human EHR analysis showed that glucosamine use was associated with a 25% increase in mortality risk in AD patients and a 35% increase in ADRD patients.
  • Glycoproteomic analysis identified a significant increase in glycopeptide abundance in AD samples, with affected glycoproteins predominantly expressed in neuronal populations.

Limitations and Future Work

  • Causality vs. Correlation: While the study strongly suggests hyper-glycosylation is a driver, establishing definitive causality in complex human diseases is always challenging.
  • Blood-Brain Barrier Permeable PGM3 Inhibitors: The authors note that no blood-brain barrier-permeable inhibitors of PGM3 currently exist, highlighting the need for developing such compounds for clinical translation.
  • Glucosamine in MCI Patients: The lack of a significant impact on mortality in the MCI cohort is noted, but the authors suggest this might be due to the heterogeneous nature of MCI diagnoses and the potential for some MCI patients to already have underlying AD.
  • Future Directions: The authors advocate for large-scale, double-blind clinical trials to definitively evaluate the impact of glucosamine on cognitive decline in dementia patients. They also suggest further research into compensatory metabolic mechanisms and the development of targeted therapies for glycan metabolism. Integrating cell-type-specific spatial information with emerging technologies is also proposed for a deeper understanding.

Summary updated

Abstract

Abstract Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by devastating degenerative decline. Metabolic disruptions are widely observed, yet their involvement in the molecular etiology of AD remains underexplored. Utilizing spatial metabolomics, lipidomics, and glycomics in both mouse models and human post-mortem samples, we identified a hyper-glycosylation phenotype as a hallmark of AD. To investigate the underlying mechanisms and whether the observed effect was a driver of the observed decline, we developed an advanced spatial isotopic tracing pulse-chase method to study the dynamics of N-linked glycans. Our analysis revealed enhanced glycan biosynthesis in AD mouse models. Based on these findings, we performed genetic and dietary interventions to modulate glycan biosynthesis. Genetic knockdown of glycan biosynthetic enzymes ameliorated the hyper-glycosylation and improved cognitive and behavioral outcomes in AD mice. In contrast, oral glucosamine supplementation drove hyper-glycosylation and exacerbated cognitive and behavioral deficits. To assess the clinical relevance of these findings, we conducted a retrospective analysis of a large population of patients with mild cognitive impairment (MCI), AD, and Alzheimer’s Disease Related Dementias ( ADRD) stratified by glucosamine use, leveraging electronic health records. Consistently, glucosamine supplementation was associated with increased mortality in AD and ADRD patient cohorts, and significantly elevated progression from MCI to AD compared to age-matched controls. Collectively, our findings establish hyper-glycosylation as a pathological driver of AD and highlight glycan metabolism as an actional target in the fight against AD.
BibTeX
@misc{hawkinson2025hyper,
  author = {Tara R. Hawkinson and Zizhen Liu and Roberto A. Ribas and Terrymar Medina and Rikke S. Nielsen and Harrison A. Clarke and Xin Ma and Ariel Mueller and Antonio Plasencia and Alexander L. Shear and Suzanne Simpson and Charles M. Soto and Jessica Sudderth and Feng Cai and Alex R. Cantrell and Matthieu G. Colpert and Cameron J. Shedlock and Lei Wu and Lyndsay E.A. Young and Damon D. Kooser and Li Chen and A Ryan and Roberto A. Ribas and Parastoo Azadi and Ralph J. DeBerardinis and Stefan Prokop and Derek B. Allison and Yu Huang and Xing He and Jiang Bian and Craig W. Vander Kooi and Matthew S. Gentry and Ramon C. Sun},
  title = {{Hyper-Glycosylation as a Central Metabolic Driver of Alzheimer’s Disease}},
  year = {2025},
  doi = {10.1101/2025.04.30.651461},
  howpublished = {bioRxiv},
}
Figure